Diamond BiofundTPE:6901 +9.86%16 ROE % is -0.63% as of Dec. 2025. GuruFocus rates TPE:6901 with a GF Score™ of 16/100. The stock has 1 warning sign investors should review. Among 1,612 Asset Management companies, Diamond Biofund ranks worse than 87.84% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Diamond Biofund's annualized net income for the quarter that ended in Dec. 2025 was NT$-58.51 Mil. Diamond Biofund's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was NT$9,223.68 Mil. Therefore, Diamond Biofund's annualized ROE % for the quarter that ended in Dec. 2025 was -0.63%.
The historical rank and industry rank for Diamond Biofund's ROE % or its related term are showing as below:
TPE:6901'
s ROE % Range Over the Past 10 Years
Min: -21.67 Med: -11.99 Max: 100.56
Current: -12.24
During the past 7 years, Diamond Biofund's highest ROE % was 100.56%. The lowest was -21.67%. And the median was -11.99%.
TPE:6901's ROE % is ranked worse than 87.84% of 1612
companies
in the Asset Management industry
Industry Median: 6.395
vs TPE:6901: -12.24
Diamond Biofund (TPE:6901) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Diamond Biofund ROE % Related Terms
Diamond Biofund ROE % Historical Data
* Premium members only.
The historical data trend for Diamond Biofund's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Diamond Biofund's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamond Biofund ROE % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Diamond Biofund's ROE % distribution charts can be found below:
* The bar in red indicates where Diamond Biofund's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Diamond Biofund (TPE:6901) has a ROE % of -0.63% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Diamond Biofund and its competitors. According to the industry distribution chart, Diamond Biofund ranks #1416 out of 1612 companies in the Asset Management industry, placing it in the top 87.8%.
Is Diamond Biofund's ROE % too high?
Diamond Biofund's current ROE % is -0.63%. Based on the distribution chart, Diamond Biofund ranks #1416 out of 1612 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, Diamond Biofund has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's ROE % compare to BLK and BX?
According to the Asset Management industry distribution chart, Diamond Biofund ranks #1416 out of 1612 companies for ROE %. This places Diamond Biofund in the lower half of its industry. The industry median ROE % is 6.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for an Asset Management company?
The median ROE % among Asset Management companies is 6.40, based on 1,612 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Diamond Biofund and its competitors. For the Asset Management industry, the median ROE % is 6.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamond Biofund's current ROE % is -0.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current ROE % of -0.63%. The current ROE % is -0.63%. Diamond Biofund's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current ROE % is -0.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
16GF Score
Get the complete analysis for TPE:6901
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6901 has been successfully added to your 
